FDA Approval Insights: Tivozanib in Relapsed/Refractory Advanced RCC

Season 1 Episode 1  ·  Jun 03, 2021, 07:58 PM

Headliner
Share
Subscribe

Dr. Rini discusses unique elements of the TIVO-3 trial, the significance of the FDA approval of tivozanib in advanced RCC, and potential next steps for research with the TKI in the paradigm.

Share
Subscribe
Next
FDA Approval Insights: Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air